Literature DB >> 24058048

C-Leg® improves function and quality of life in an adolescent traumatic trans-femoral amputee: a case study.

Louise J Tofts1, Natasha Hamblin2.   

Abstract

BACKGROUND AND AIMS: (1) To demonstrate that a 13-year-old male can be successfully fitted with a C-Leg® microprocessor-controlled knee. (2) To use validated outcome measurement tools to assess change in mobility, physical function, fatigue and quality of life after fitting. CASE DESCRIPTION AND METHODS: A 13-year-old unilateral traumatic trans-femoral amputee was studied pre-C-Leg fitting and 2 weeks and 10 months post C-Leg fitting. FINDINGS AND OUTCOMES: The 6-Minute Walk Test improved by 33% from 360 to 480 m. PedsQL™ Multidimensional Fatigue Scale improved by 32% from 68 to 90, and PedsQL™ Quality of Life Scale improved 14 points, with minimal clinically important difference of 4.36 points.
CONCLUSION: In this case, the provision of a microprocessor-controlled knee in the context of a new prosthesis with new socket system produced improvements for the patient in walking speed, fatigue and quality of life. CLINICAL RELEVANCE: This case report shows that n = 1 methodology can be used to demonstrate clinical improvement in an adolescent subject when using an intervention (C-Leg) which is not supported in this age group by published evidence. © The International Society for Prosthetics and Orthotics 2013.

Entities:  

Keywords:  Adolescent; microprocessor-controlled knee

Mesh:

Year:  2013        PMID: 24058048     DOI: 10.1177/0309364613502354

Source DB:  PubMed          Journal:  Prosthet Orthot Int        ISSN: 0309-3646            Impact factor:   1.895


  1 in total

1.  The Kenevo microprocessor-controlled prosthetic knee compared with non-microprocessor-controlled knees in individuals older than 65 years in Sweden: A cost-effectiveness and budget-impact analysis.

Authors:  Alexander Kuhlmann; Kerstin Hagberg; Ilka Kamrad; Nerrolyn Ramstrand; Susanne Seidinger; Hans Berg
Journal:  Prosthet Orthot Int       Date:  2022-05-03       Impact factor: 1.672

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.